DRIVIN G ROWTH - Dr. Reddy's

166
statement pursuant to section 212 of the companies act, 1956 relating to
subsidiary companies
Reddy Netherlands BV
Kunshan Rotam Reddy
Pharmaceutical Co. Ltd.
Zenovus Biotech Pvt. Ltd.
Aurigene Discovery
Technologies Ltd.
Cheminor Investments
Ltd.
Reddy Cheminor S.A.
Reddy US Therapeutics Inc.
Reddy Pharmaceuticals
Singapore Pte. Ltd.
Dr. Reddy’s
Laboratories Inc.
Dr. Reddy’s Farmaceutica
Do Brasil Ltda.
Reddy Antilles N.V.
OOO JV Reddy Biomed
Ltd.
Reddy Pharmaceuticals
Hongkong Ltd.
Compact Electric
Ltd.
DRL Investments
Ltd.
Name of the subsidiary
The Financial Year of the
subsidiary company ended on 31.03.2002 31.03.2002 31.12.2001 31.12.2001 31.12.2001 31.12.2001 31.03.2002 31.12.2001 31.03.2002 31.03.2002 31.03.2002 31.03.2002 31.03.2002 31.12.2001 31.12.2001
Number of shares in the subsidiary company held by Dr. Reddy Laboratories Limited at the above date
Equity Shares 104 800000 11625000 380000 500000 400000 400750 * * 2494 134513 10004 10000 ** *
Preference Shares 8 700,070 – – – – – – – – 8 – – – –
Equity Holding 100% 100% 100% 76% 100% 100% 100% * * 99.76% 100% 100% 100% 51% *
STATEMENT UNDER SECTION 212 | FINANCIALS | ANNUAL REPORT 2001-2002
Preference Holding 0% 100% – – – – – – – – 0% – – – –
The net Aggregate of profits (losses) of the subsidiary company for it’s financial year so far as they concern the members of Dr. Reddy’s Laboratories Limited
a) Dealt with in the account of
Dr. Reddy’s Laboratories Limited
for the year ended 31.03.2002 Nil Nil Nil Nil Nil Nil Nil Nil Nil Nil Nil Nil Nil Nil Nil
b) Not dealt with in the account of
Dr. Reddy’s Laboratories Limited Rs. Rs. US$ Roubles US$ E US$ S$ US$ E Rs. RMB NLG
for the year ended 31.03.2002 (21,307) (7,810,489) 89,910 45,645,000 (14,998) (217,815) 845,339 (97,962) 158,038 124,929 (2,137) – – (2,654,841) (79,111)